NO321735B1 - Anvendelse av et piperazinderivat for fremstilling av et preventiv eller terapeutisk middel mot stoffavhengighet - Google Patents

Anvendelse av et piperazinderivat for fremstilling av et preventiv eller terapeutisk middel mot stoffavhengighet Download PDF

Info

Publication number: NO321735B1
Authority: NO; Norway
Prior art keywords: drug addiction; rats; preventive; carbon atoms; addictive substances
Prior art date: 1998-11-09

Application number

NO20012226A

Other languages

English (en)

Norwegian (no)

Other versions

NO20012226L (no

NO20012226D0 (no

Inventor

Kiyoshi Matsuno

Tsutomu Suzuki

Shiro Mita

Original Assignee

Santen Pharmaceutical Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-11-09

Filing date

2001-05-04

Publication date

2006-06-26

2001-05-04 Application filed by Santen Pharmaceutical Co Ltd filed Critical Santen Pharmaceutical Co Ltd

2001-05-04 Publication of NO20012226D0 publication Critical patent/NO20012226D0/no

2001-06-12 Publication of NO20012226L publication Critical patent/NO20012226L/no

2006-06-26 Publication of NO321735B1 publication Critical patent/NO321735B1/no

Links

208000011117 substance-related disease Diseases 0.000 title claims description 31
239000003814 drug Substances 0.000 title claims description 25
206010013663 drug dependence Diseases 0.000 title claims description 24
150000004885 piperazines Chemical class 0.000 title claims description 12
229940124597 therapeutic agent Drugs 0.000 title claims description 8
230000003449 preventive effect Effects 0.000 title claims description 7
238000002360 preparation method Methods 0.000 title description 6
150000001875 compounds Chemical class 0.000 claims description 41
BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 claims description 16
150000003839 salts Chemical class 0.000 claims description 16
ZPUCINDJVBIVPJ-LJISPDSOSA-N ***e Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 claims description 15
125000004432 carbon atom Chemical group C* 0.000 claims description 12
125000002947 alkylene group Chemical group 0.000 claims description 8
229960005181 morphine Drugs 0.000 claims description 8
229960003920 ***e Drugs 0.000 claims description 7
125000003545 alkoxy group Chemical group 0.000 claims description 6
239000004480 active ingredient Substances 0.000 claims description 5
229960001252 methamphetamine Drugs 0.000 claims description 5
MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 claims description 5
125000003310 benzodiazepinyl group Chemical class N1N=C(C=CC2=C1C=CC=C2)* 0.000 claims description 3
238000004519 manufacturing process Methods 0.000 claims description 3
JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 claims description 3
SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims description 2
229960002715 nicotine Drugs 0.000 claims description 2
SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims description 2
229950010883 phencyclidine Drugs 0.000 claims description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
239000000126 substance Substances 0.000 description 32
241000700159 Rattus Species 0.000 description 29
238000012360 testing method Methods 0.000 description 24
229940079593 drug Drugs 0.000 description 17
239000000243 solution Substances 0.000 description 16
230000000694 effects Effects 0.000 description 13
238000000034 method Methods 0.000 description 12
230000003750 conditioning effect Effects 0.000 description 11
229940066771 systemic antihistamines piperazine derivative Drugs 0.000 description 10
239000002504 physiological saline solution Substances 0.000 description 8
238000005192 partition Methods 0.000 description 7
229940126062 Compound A Drugs 0.000 description 6
NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 6
230000001143 conditioned effect Effects 0.000 description 6
230000001186 cumulative effect Effects 0.000 description 6
210000003169 central nervous system Anatomy 0.000 description 5
230000000144 pharmacologic effect Effects 0.000 description 5
PIQVDUKEQYOJNR-VZXSFKIWSA-N ***e hydrochloride Chemical compound [Cl-].O([C@H]1C[C@@H]2CC[C@@H]([NH+]2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 PIQVDUKEQYOJNR-VZXSFKIWSA-N 0.000 description 4
229960003771 ***e hydrochloride Drugs 0.000 description 4
RHCSKNNOAZULRK-UHFFFAOYSA-N mescaline Chemical compound COC1=CC(CCN)=CC(OC)=C1OC RHCSKNNOAZULRK-UHFFFAOYSA-N 0.000 description 4
229960005195 morphine hydrochloride Drugs 0.000 description 4
XELXKCKNPPSFNN-BJWPBXOKSA-N morphine hydrochloride trihydrate Chemical compound O.O.O.Cl.O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O XELXKCKNPPSFNN-BJWPBXOKSA-N 0.000 description 4
-1 thinners Chemical class 0.000 description 4
206010013654 Drug abuse Diseases 0.000 description 3
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
230000002401 inhibitory effect Effects 0.000 description 3
TWXDDNPPQUTEOV-FVGYRXGTSA-N methamphetamine hydrochloride Chemical compound Cl.CN[C@@H](C)CC1=CC=CC=C1 TWXDDNPPQUTEOV-FVGYRXGTSA-N 0.000 description 3
229960002532 methamphetamine hydrochloride Drugs 0.000 description 3
201000009032 substance abuse Diseases 0.000 description 3
208000024891 symptom Diseases 0.000 description 3
KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 2
USSIQXCVUWKGNF-UHFFFAOYSA-N 6-(dimethylamino)-4,4-diphenylheptan-3-one Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 description 2
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
244000025254 Cannabis sativa Species 0.000 description 2
235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 description 2
235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 description 2
206010012335 Dependence Diseases 0.000 description 2
VAYOSLLFUXYJDT-RDTXWAMCSA-N Lysergic acid diethylamide Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N(CC)CC)C2)=C3C2=CNC3=C1 VAYOSLLFUXYJDT-RDTXWAMCSA-N 0.000 description 2
XADCESSVHJOZHK-UHFFFAOYSA-N Meperidine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
150000001298 alcohols Chemical class 0.000 description 2
229940025084 amphetamine Drugs 0.000 description 2
229940053197 benzodiazepine derivative antiepileptics Drugs 0.000 description 2
230000037396 body weight Effects 0.000 description 2
RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
239000002775 capsule Substances 0.000 description 2
238000007405 data analysis Methods 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
239000008187 granular material Substances 0.000 description 2
239000000380 hallucinogen Substances 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
240000004308 marijuana Species 0.000 description 2
238000000691 measurement method Methods 0.000 description 2
229960001797 methadone Drugs 0.000 description 2
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
239000000014 opioid analgesic Substances 0.000 description 2
239000003960 organic solvent Substances 0.000 description 2
229960000482 pethidine Drugs 0.000 description 2
230000010411 postconditioning Effects 0.000 description 2
ODLMAHJVESYWTB-UHFFFAOYSA-N propylbenzene Chemical compound CCCC1=CC=CC=C1 ODLMAHJVESYWTB-UHFFFAOYSA-N 0.000 description 2
230000002385 psychotomimetic effect Effects 0.000 description 2
229940125723 sedative agent Drugs 0.000 description 2
239000000932 sedative agent Substances 0.000 description 2
238000013222 sprague-dawley male rat Methods 0.000 description 2
231100000736 substance abuse Toxicity 0.000 description 2
201000006152 substance dependence Diseases 0.000 description 2
239000003826 tablet Substances 0.000 description 2
VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
238000012549 training Methods 0.000 description 2
OOBHFESNSZDWIU-GXSJLCMTSA-N (2s,3s)-3-methyl-2-phenylmorpholine Chemical compound C[C@@H]1NCCO[C@H]1C1=CC=CC=C1 OOBHFESNSZDWIU-GXSJLCMTSA-N 0.000 description 1
WRRSFOZOETZUPG-FFHNEAJVSA-N (4r,4ar,7s,7ar,12bs)-9-methoxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7-ol;hydrate Chemical compound O.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC WRRSFOZOETZUPG-FFHNEAJVSA-N 0.000 description 1
208000019901 Anxiety disease Diseases 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
206010012289 Dementia Diseases 0.000 description 1
206010012689 Diabetic retinopathy Diseases 0.000 description 1
240000006890 Erythroxylum coca Species 0.000 description 1
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
208000010412 Glaucoma Diseases 0.000 description 1
239000004866 Hashish Substances 0.000 description 1
GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 description 1
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
NPPQSCRMBWNHMW-UHFFFAOYSA-N Meprobamate Chemical compound NC(=O)OCC(C)(CCC)COC(N)=O NPPQSCRMBWNHMW-UHFFFAOYSA-N 0.000 description 1
JEYCTXHKTXCGPB-UHFFFAOYSA-N Methaqualone Chemical compound CC1=CC=CC=C1N1C(=O)C2=CC=CC=C2N=C1C JEYCTXHKTXCGPB-UHFFFAOYSA-N 0.000 description 1
DUGOZIWVEXMGBE-UHFFFAOYSA-N Methylphenidate Chemical compound C=1C=CC=CC=1C(C(=O)OC)C1CCCCN1 DUGOZIWVEXMGBE-UHFFFAOYSA-N 0.000 description 1
239000008896 Opium Substances 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
208000008469 Peptic Ulcer Diseases 0.000 description 1
QVDSEJDULKLHCG-UHFFFAOYSA-N Psilocybine Natural products C1=CC(OP(O)(O)=O)=C2C(CCN(C)C)=CNC2=C1 QVDSEJDULKLHCG-UHFFFAOYSA-N 0.000 description 1
208000017442 Retinal disease Diseases 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
239000000556 agonist Substances 0.000 description 1
238000011292 agonist therapy Methods 0.000 description 1
239000002269 analeptic agent Substances 0.000 description 1
229940035676 analgesics Drugs 0.000 description 1
229940124332 anorexigenic agent Drugs 0.000 description 1
230000003042 antagnostic effect Effects 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
239000000730 antalgic agent Substances 0.000 description 1
239000002249 anxiolytic agent Substances 0.000 description 1
230000000949 anxiolytic effect Effects 0.000 description 1
229940005530 anxiolytics Drugs 0.000 description 1
239000002830 appetite depressant Substances 0.000 description 1
229940125717 barbiturate Drugs 0.000 description 1
150000007656 barbituric acids Chemical class 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 description 1
229960001736 buprenorphine Drugs 0.000 description 1
125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
229960001948 caffeine Drugs 0.000 description 1
VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
239000011575 calcium Substances 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
230000002490 cerebral effect Effects 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 1
229960002327 chloral hydrate Drugs 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
235000008957 cocaer Nutrition 0.000 description 1
229960004126 codeine Drugs 0.000 description 1
OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Natural products C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 1
229960002069 diamorphine Drugs 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
230000004064 dysfunction Effects 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
150000004677 hydrates Chemical class 0.000 description 1
150000003840 hydrochlorides Chemical class 0.000 description 1
OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 1
239000001863 hydroxypropyl cellulose Substances 0.000 description 1
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
230000000147 hypnotic effect Effects 0.000 description 1
208000026278 immune system disease Diseases 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
230000003993 interaction Effects 0.000 description 1
150000003893 lactate salts Chemical class 0.000 description 1
239000008101 lactose Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
229960003511 macrogol Drugs 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
150000002688 maleic acid derivatives Chemical class 0.000 description 1
238000005259 measurement Methods 0.000 description 1
229960004815 meprobamate Drugs 0.000 description 1
229960002803 methaqualone Drugs 0.000 description 1
229960001344 methylphenidate Drugs 0.000 description 1
230000003533 narcotic effect Effects 0.000 description 1
210000005036 nerve Anatomy 0.000 description 1
210000002569 neuron Anatomy 0.000 description 1
229940005483 opioid analgesics Drugs 0.000 description 1
229960001027 opium Drugs 0.000 description 1
150000003891 oxalate salts Chemical class 0.000 description 1
VOKSWYLNZZRQPF-GDIGMMSISA-N pentazocine Chemical compound C1C2=CC=C(O)C=C2[C@@]2(C)[C@@H](C)[C@@H]1N(CC=C(C)C)CC2 VOKSWYLNZZRQPF-GDIGMMSISA-N 0.000 description 1
229960005301 pentazocine Drugs 0.000 description 1
208000011906 peptic ulcer disease Diseases 0.000 description 1
238000001050 pharmacotherapy Methods 0.000 description 1
229960003209 phenmetrazine Drugs 0.000 description 1
235000021317 phosphate Nutrition 0.000 description 1
150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
229960000753 pipradrol Drugs 0.000 description 1
XSWHNYGMWWVAIE-UHFFFAOYSA-N pipradrol Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(O)C1CCCCN1 XSWHNYGMWWVAIE-UHFFFAOYSA-N 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
230000002265 prevention Effects 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
QKTAAWLCLHMUTJ-UHFFFAOYSA-N psilocybin Chemical compound C1C=CC(OP(O)(O)=O)=C2C(CCN(C)C)=CN=C21 QKTAAWLCLHMUTJ-UHFFFAOYSA-N 0.000 description 1
230000004800 psychological effect Effects 0.000 description 1
230000002207 retinal effect Effects 0.000 description 1
210000001210 retinal vessel Anatomy 0.000 description 1
201000000980 schizophrenia Diseases 0.000 description 1
239000003982 sigma receptor ligand Substances 0.000 description 1
229920002050 silicone resin Polymers 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000000021 stimulant Substances 0.000 description 1
150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
238000010998 test method Methods 0.000 description 1
125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
239000003204 tranquilizing agent Substances 0.000 description 1
230000002936 tranquilizing effect Effects 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Biomedical Technology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Psychiatry (AREA)
Addiction (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

NO20012226A 1998-11-09 2001-05-04 Anvendelse av et piperazinderivat for fremstilling av et preventiv eller terapeutisk middel mot stoffavhengighet NO321735B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP31746898		1998-11-09
PCT/JP1999/006148 WO2000027833A1 (fr)	1998-11-09	1999-11-04	Medicaments contre la dependance aux drogues

Publications (3)

Publication Number	Publication Date
NO20012226D0 NO20012226D0 (no)	2001-05-04
NO20012226L NO20012226L (no)	2001-06-12
NO321735B1 true NO321735B1 (no)	2006-06-26

Family

ID=18088576

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20012226A NO321735B1 (no)	1998-11-09	2001-05-04	Anvendelse av et piperazinderivat for fremstilling av et preventiv eller terapeutisk middel mot stoffavhengighet

Country Status (9)

Country	Link
US (1)	US6492369B2 (de)
EP (1)	EP1130018B1 (de)
KR (1)	KR100700347B1 (de)
CN (1)	CN1131221C (de)
CA (1)	CA2349452C (de)
DE (1)	DE69934902T2 (de)
ES (1)	ES2281196T3 (de)
NO (1)	NO321735B1 (de)
WO (1)	WO2000027833A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2116539A1 (de)	2008-04-25	2009-11-11	Laboratorios Del. Dr. Esteve, S.A.	1-Aryl-3-Amino-alkoxy-pyrazole als Sigma-Liganden zur Verbesserung der analgetischen Wirkung von Opioiden und zur Schwächung der Abhängigkeit davon
EP2353598A1 (de)	2010-02-04	2011-08-10	Laboratorios Del. Dr. Esteve, S.A.	Sigma-Liganden zur Anwendung in der Vorbeugung und/oder Behandlung von postoperativem Schmerz
EP2353591A1 (de)	2010-02-04	2011-08-10	Laboratorios Del. Dr. Esteve, S.A.	Sigma-Liganden zur Verstärkung der analgesischen Wirkung von Opioden und Opiaten bei postoperativem Schmerz und zur Schwächung der Abhängigkeit davon
EP2388005A1 (de)	2010-05-21	2011-11-23	Laboratorios Del. Dr. Esteve, S.A.	Sigma-Liganden zur Vorbeugung und/oder Behandlung von Erbrechen infolge von Chemotherapie oder Strahlentherapie
EP2415471A1 (de)	2010-08-03	2012-02-08	Laboratorios Del. Dr. Esteve, S.A.	Verwendung von Sigmaliganden bei opioidinduzierter Hyperalgesie
EP2524694A1 (de)	2011-05-19	2012-11-21	Laboratorios Del. Dr. Esteve, S.A.	Verwendung von Sigmaliganden bei Schmerz im Zusammenhang mit Typ-2-Diabetes
WO2015091508A1 (en)	2013-12-17	2015-06-25	Laboratorios Del Dr. Esteve, S.A.	SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIs) AND SIGMA RECEPTOR LIGANDS COMBINATIONS

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5556857A (en) *	1991-05-08	1996-09-17	Otsuka Pharmaceutical Co., Ltd.	Disturbance-of-consciousness improving agent
JPH06509069A (ja) *	1991-06-27	1994-10-13	バージニア・コモンウェルス・ユニバーシティ	シグマレセプターリガンドおよびその用途
CA2166100A1 (en) *	1993-06-23	1995-01-05	Richard A. Glennon	Sigma receptor ligands and the use thereof
ATE197047T1 (de) *	1993-07-28	2000-11-15	Santen Pharmaceutical Co Ltd	1,4-di(phenylalkyl)piperazinderivate
JP2883970B2 (ja)	1993-07-28	1999-04-19	参天製薬株式会社	新規１，４−（ジフェニルアルキル）ピペラジン誘導体
JPH10120569A (ja)	1996-10-21	1998-05-12	Santen Pharmaceut Co Ltd	眼疾患予防または治療剤

1999
- 1999-11-04 CA CA002349452A patent/CA2349452C/en not_active Expired - Fee Related
- 1999-11-04 CN CN99813110A patent/CN1131221C/zh not_active Expired - Fee Related
- 1999-11-04 WO PCT/JP1999/006148 patent/WO2000027833A1/ja active IP Right Grant
- 1999-11-04 DE DE69934902T patent/DE69934902T2/de not_active Expired - Lifetime
- 1999-11-04 EP EP99954381A patent/EP1130018B1/de not_active Expired - Lifetime
- 1999-11-04 KR KR1020017005777A patent/KR100700347B1/ko not_active IP Right Cessation
- 1999-11-04 ES ES99954381T patent/ES2281196T3/es not_active Expired - Lifetime
2001
- 2001-05-04 NO NO20012226A patent/NO321735B1/no not_active IP Right Cessation
- 2001-05-07 US US09/850,431 patent/US6492369B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
EP1130018A4 (de)	2003-01-15
ES2281196T3 (es)	2007-09-16
CN1131221C (zh)	2003-12-17
NO20012226L (no)	2001-06-12
EP1130018B1 (de)	2007-01-17
NO20012226D0 (no)	2001-05-04
CN1325391A (zh)	2001-12-05
US20020019399A1 (en)	2002-02-14
CA2349452C (en)	2009-02-10
CA2349452A1 (en)	2000-05-18
US6492369B2 (en)	2002-12-10
WO2000027833A1 (fr)	2000-05-18
DE69934902T2 (de)	2007-10-18
EP1130018A1 (de)	2001-09-05
KR100700347B1 (ko)	2007-03-29
DE69934902D1 (de)	2007-03-08
KR20010089413A (ko)	2001-10-06

Legal Events

Date	Code	Title	Description
2012-06-25	MM1K	Lapsed by not paying the annual fees

Publication	Publication Date	Title
EP0799037B1 (de)	2006-09-20	Mittel zur behandlung der allergischen rhinitis und anderer erkrankungen enthaltend descarboethoxyloratadin
Fiorella et al.	1995	The role of the 5-HT2A and 5-HT2C receptors in the stimulus effects of hallucinogenic drugs I: Antagonist correlation analysis
EP0163697B1 (de)	1990-05-23	Schnelles verfahren zur unterbrechung des gewöhnungssyndroms für narkotika
Papeschi et al.	1971	The effect of yohimbine on brain serotonin metabolism, motor behavior and body temperature of the rat
US6077846A (en)	2000-06-20	Epibatidine and derivatives thereof as cholinergic receptor agonists and antagonists
NO321735B1 (no)	2006-06-26	Anvendelse av et piperazinderivat for fremstilling av et preventiv eller terapeutisk middel mot stoffavhengighet
CN1307147C (zh)	2007-03-28	作为5－ht3和神经元烟碱性受体拮抗剂的1－氨基－烷基环己烷
Jaeger et al.	1990	A taste aversion model of drug discrimination learning: training drug and condition influence rate of learning, sensitivity and drug specificity
US9192605B2 (en)	2015-11-24	Compositions and methods for treating parkinson's disease
EP1512679A1 (de)	2005-03-09	Adamantanderivate mit Neuroprotektoren, Antidepressoren und antiischaemischer Wirkung, und Verfahren zur ihrer Herstellung
Nielsen et al.	1988	Central nervous system stimulants: Neuropharmacological mechanisms
CA2386149A1 (en)	2001-04-26	Allosteric sites on muscarinic receptors
JP3752580B2 (ja)	2006-03-08	薬物依存症治療剤
US5574041A (en)	1996-11-12	Use of spiperone derivatives as immunosuppressant agents
Ally et al.	1995	Cardiovascular effects elicited by central administration of physostigmine via M2 muscarinic receptors in conscious cats
NO316611B1 (no)	2004-03-08	Anvendelse av pyridyl- og pyrimidylpiperaziner i behandling av substansmisbruksforstyrrelser
RU2277096C2 (ru)	2006-05-27	Средства против слабоумия, содержащие производное 2-арил-8-оксодигидропурина в качестве активного ингредиента
EP0818198A1 (de)	1998-01-14	Potenzierung von Wirkstoffresponz durch erhöhte Verfügung von Serotonin
Slomka et al.	1952	Chemical constitution and analgetic action
Mohrland et al.	1985	The analgesic activity of a clonidine analog: the formamidine, U-47,476 A
WO1995003048A1 (en)	1995-02-02	Anti-hiv azaspiranes
WO1989010741A1 (en)	1989-11-16	Anxiolytic/anti-depressant 2,3-dihydro-1h-phenalen-2-amines
Convulsions	1982	DIFFERENTIAL EFFECT OF YOHIMBINE IN SEVERAL CHEMICAL MODELS OF CONVULSIONS IN MICE
Quan-sheng et al.	1990	Use of nitrogen and inhibitor for studying the quantitative properties of calcium transport
MXPA00009464A (en)	2001-07-31	Methods and compositions for treating allergic rhinitis and other disorders using descarboethoxyloratadine